Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: regorafenib
Trade Name: Stivarga
Date Designated: 01/12/2011
Orphan Designation: Treatment gastrointestinal stromal tumors
Orphan Designation Status: Designated/Approved
Bayer HealthCare Pharmaceuticals, Inc.
P. O. Box 1000
Montvale, New Jersey 07045
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: regorafenib
Trade Name: Stivarga
Marketing Approval Date: 02/25/2013
Approved Labeled Indication: Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.
Exclusivity End Date: 02/25/2020 
Exclusivity Protected Indication* :  Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.
*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.
-
-